 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...3031323334353637383940...4142» |
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Dec 21, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2016 --> Sep 2017
- || New P3 trial: Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients (clinicaltrials.gov) - Dec 15, 2016
P3, N=104, Recruiting, Sponsor: Dharmais National Cancer Center Hospital
- |||||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Metastases: MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) - Dec 14, 2016
P3, N=450, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Sep 2016 --> Sep 2017 Not yet recruiting --> Recruiting
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Dec 12, 2016
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> May 2017
- | anastrozole / Generic mfg., fulvestrant / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Surgery: Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. (clinicaltrials.gov) - Dec 1, 2016
P2, N=42, Active, not recruiting, Sponsor: University of Kansas Medical Center
Trial primary completion date: Nov 2016 --> May 2017 Recruiting --> Active, not recruiting | N=32 --> 42 | Trial primary completion date: Sep 2015 --> Apr 2015
- |||| Enrollment open, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 29, 2016
P4, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=32 --> 42 | Trial primary completion date: Sep 2015 --> Apr 2015 Active, not recruiting --> Recruiting
- |||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Metastases: KEYNOTE 287: A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (clinicaltrials.gov) - Nov 25, 2016
P2, N=75, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Firmagon (degarelix) / Astellas, Ferring
Enrollment closed: Impact of Estradiol Addback (clinicaltrials.gov) - Nov 23, 2016
P1, N=60, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Ibrance (palbociclib) / Pfizer
Enrollment open, Metastases: Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - Nov 22, 2016
P2, N=40, Recruiting, Sponsor: Antoinette Tan
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- anastrozole / Generic mfg.
New P4 trial: Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) (clinicaltrials.gov) - Nov 8, 2016
P4, N=20, Recruiting, Sponsor: Baylor College of Medicine
- |||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Trial completion: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Nov 3, 2016
P2b, N=305, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change, Trial initiation date, Trial primary completion date: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Oct 31, 2016
P2, N=50, Not yet recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed N=70 --> 50 | Initiation date: Oct 2016 --> Jan 2017 | Trial primary completion date: Oct 2023 --> Jul 2018
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - Oct 27, 2016
P3, N=496, Not yet recruiting, Sponsor: Alliance Foundation Trials, LLC.
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open, Metastases: INGE-B: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (clinicaltrials.gov) - Oct 25, 2016
P2, N=120, Recruiting, Sponsor: iOMEDICO AG
N=70 --> 50 | Initiation date: Oct 2016 --> Jan 2017 | Trial primary completion date: Oct 2023 --> Jul 2018 Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Metastases: Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - Oct 25, 2016
P2, N=40, Not yet recruiting, Sponsor: Antoinette Tan
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Oct 14, 2016
P2, N=32, Recruiting, Sponsor: Midwestern Regional Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- |||||||||| New P3 trial: GIM10-CONSENT: CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (clinicaltrials.gov) - Sep 28, 2016
P3, N=1000, Recruiting, Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- everolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Sep 26, 2016
P2, N=4, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=38 --> 4 | Trial primary completion date: Feb 2017 --> Sep 2017
- ||||||| rhGH-Emisphere (somatropin oral, oral recombinant human growth hormone) / Novo Nordisk, Ligand, Genotropin (somatropin) / Pfizer, Nutropin AQ (somatropin) / Ipsen, Roche
Trial completion, Combination therapy: ThrasherAI: Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature (clinicaltrials.gov) - Sep 23, 2016
P3, N=77, Completed, Sponsor: Nemours Children's Clinic
Recruiting --> Active, not recruiting | N=38 --> 4 | Trial primary completion date: Feb 2017 --> Sep 2017 Active, not recruiting --> Completed
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Sep 23, 2016
P3, N=671, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | bicalutamide / Generic mfg.
New P2 trial, Metastases: Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer (clinicaltrials.gov) - Sep 21, 2016
P2, N=58, Recruiting, Sponsor: Xu fei
- everolimus / Generic mfg.
Trial primary completion date, Metastases: MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Sep 19, 2016
P3, N=253, Recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Feb 2018
- Enrollment open: CardioVOLT: Cardiovascular Outcomes of Low Testosterone (clinicaltrials.gov) - Sep 19, 2016
P=N/A, N=379, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Feb 2017 --> Feb 2018 Active, not recruiting --> Recruiting
- | anastrozole / Generic mfg., fulvestrant / Generic mfg.
Enrollment open: ALTERNATE: Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Sep 16, 2016
P3, N=2820, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Recruiting Suspended --> Recruiting
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Phase classification, Enrollment change: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Sep 14, 2016
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Suspended --> Recruiting Active, not recruiting --> Recruiting | Phase classification: P1 --> P1b | N=102 --> 123
- ||||| Ibrance (palbociclib) / Pfizer
New P2 trial, Metastases: INGE-B: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (clinicaltrials.gov) - Sep 9, 2016
P2, N=120, Not yet recruiting, Sponsor: iOMEDICO AG
- ||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Trial completion: Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring (clinicaltrials.gov) - Sep 7, 2016
P1, N=52, Completed, Sponsor: Bayer
Active, not recruiting --> Recruiting | Phase classification: P1 --> P1b | N=102 --> 123 Active, not recruiting --> Completed
- anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial suspension: ALTERNATE: Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Sep 2, 2016
P3, N=2820, Suspended, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Recruiting --> Suspended
- |||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
Enrollment open, Trial primary completion date: Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer (clinicaltrials.gov) - Aug 24, 2016
P2, N=112, Recruiting, Sponsor: Baylor Breast Care Center
Recruiting --> Suspended Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Jul 2017
- || miransertib (MK-7075) / Merck (MSD)
Phase classification, Enrollment change, Trial primary completion date, Combination therapy: Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole (clinicaltrials.gov) - Aug 19, 2016
P1b, N=52, Recruiting, Sponsor: ArQule
Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Jul 2017 Phase classification: P1 --> P1b | N=40 --> 52 | Trial primary completion date: Dec 2016 --> Jun 2017
- Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial primary completion date, Combination therapy, Monotherapy, Metastases: TREnd: To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy (clinicaltrials.gov) - Aug 9, 2016
P2, N=115, Active, not recruiting, Sponsor: Fondazione Sandro Pitigliani
Phase classification: P1 --> P1b | N=40 --> 52 | Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Enrollment change, Combination therapy, Monotherapy: neoMONARCH: A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Jul 23, 2016
P2, N=148, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=220 --> 148
- || Trial primary completion date, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Jul 19, 2016
P2, N=317, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=220 --> 148 Trial primary completion date: Nov 2016 --> Oct 2017
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Jul 1, 2016
P3, N=10000, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2016 --> Oct 2017 N=5000 --> 10000
- letrozole / Generic mfg., anastrozole / Generic mfg.
New trial: Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=1000, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- saracatinib (AZD0530) / AstraZeneca
Enrollment open, Phase classification: A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Jun 22, 2016
P2, N=72, Recruiting, Sponsor: Joyce Marie Slingerland
N=5000 --> 10000 Suspended --> Recruiting | Phase classification: P1/2 --> P2
- || Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Trial primary completion date, Metastases: CHEOPS: Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (clinicaltrials.gov) - Jun 16, 2016
P2, N=130, Recruiting, Sponsor: ARCAGY/ GINECO GROUP
Suspended --> Recruiting | Phase classification: P1/2 --> P2 Trial primary completion date: May 2016 --> Sep 2017
- anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial primary completion date: ALTERNATE: Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Jun 13, 2016
P3, N=2820, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: May 2016 --> Sep 2017 Trial primary completion date: Apr 2016 --> Apr 2020
- ||||||| anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: SWOG-NSABP-B-35: Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy (clinicaltrials.gov) - Jun 11, 2016
P3, N=3104, Completed, Sponsor: NSABP Foundation Inc
Trial primary completion date: Apr 2016 --> Apr 2020 Active, not recruiting --> Completed
- Trial initiation date, Trial primary completion date: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Jun 5, 2016
P2, N=70, Not yet recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Initiation date: Feb 2016 --> Oct 2016 | Trial primary completion date: Feb 2023 --> Oct 2023
- vistusertib (AZD2014) / AstraZeneca
Enrollment open, Combination therapy, IO biomarker, Metastases: Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (clinicaltrials.gov) - Jun 1, 2016
P1/2, N=72, Recruiting, Sponsor: Centre Leon Berard
Initiation date: Feb 2016 --> Oct 2016 | Trial primary completion date: Feb 2023 --> Oct 2023 Not yet recruiting --> Recruiting
- ||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Enrollment closed: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - May 27, 2016
P2b, N=318, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- pazopanib / Generic mfg., anastrozole / Generic mfg.
Trial completion: Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer (clinicaltrials.gov) - May 26, 2016
P2, N=2, Completed, Sponsor: University of Arizona
Recruiting --> Active, not recruiting Terminated --> Completed
- | anastrozole / Generic mfg., tamoxifen / Generic mfg., toremifene / Generic mfg.
Enrollment open: Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer (clinicaltrials.gov) - May 25, 2016
P3, N=600, Recruiting, Sponsor: Peking Union Medical College Hospital
Terminated --> Completed Active, not recruiting --> Recruiting
- ||||| Verzenio (abemaciclib) / Eli Lilly
New P2 trial, Metastases: KEYNOTE 287: A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (clinicaltrials.gov) - May 20, 2016
P2, N=75, Not yet recruiting, Sponsor: Eli Lilly and Company
- saracatinib (AZD0530) / AstraZeneca
Trial suspension: A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - May 13, 2016
P1/2, N=72, Suspended, Sponsor: Joyce Marie Slingerland
Active, not recruiting --> Recruiting Recruiting --> Suspended
- ||||||| anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: DATA: Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer (clinicaltrials.gov) - May 13, 2016
P3, N=1914, Completed, Sponsor: AstraZeneca
Recruiting --> Suspended Active, not recruiting --> Completed
- || anastrozole / Generic mfg., tamoxifen / Generic mfg., fulvestrant / Generic mfg.
Trial primary completion date: Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - May 11, 2016
P2, N=250, Recruiting, Sponsor: The Netherlands Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2018
- letrozole / Generic mfg., anastrozole / Generic mfg.
Enrollment open: GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) - May 11, 2016
P=N/A, N=90, Recruiting, Sponsor: University of Maryland
Trial primary completion date: Jun 2016 --> Jun 2018 Not yet recruiting --> Recruiting
- || capecitabine / Generic mfg.
New P3 trial, Metastases: MECCA: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (clinicaltrials.gov) - May 10, 2016
P3, N=240, Not yet recruiting, Sponsor: Sun Yat-sen University